A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 4, 2014, Pages 490-506

  Moosa, Raeesa M ^a   Choonara, Yahya E ^a   Du Toit, Lisa C ^a   Kumar, Pradeep ^a   Carmichael, Trevor ^b   Tomar, Lomas Kumar ^a   Tyagi, Charu ^a   Pillay, Viness ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

anterior segment of the eye; drug delivery; mini tablets; rapidly dissolving tablet

Indexed keywords

ANTERIOR SEGMENT OF THE EYE; DRUG DELIVERY; MINI-TABLETS; RAPIDLY DISSOLVING TABLET;

ADMINISTRATION, TOPICAL; ANTERIOR EYE SEGMENT; DRUG DELIVERY SYSTEMS; HUMANS; TABLETS;

EID: 84899096928     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12131     Document Type: Review

References (115)

1. Pascolini D, Mariotti SPM,. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012; 96: 614-618.
2. Robinson JC,. Ocular anatomy and physiology relevant to ocular drug delivery. In:, Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker, 1993: 29-58.
3. Ding S,. Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today 1998; 1: 328-335.
4. Anumolu SS, etal. Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response. J Control Release 2009; 137: 152-159.
5. Kompella UB, etal. Recent advances in ophthalmic drug delivery. Ther Deliv 2010; 1: 435-456.
6. Weiner AL, Gilger BC,. Advancements in ocular drug delivery. Vet Ophthalmol 2010; 6: 395-406.
7. Weiner A,. Drug delivery systems in ophthalmic applications. In:, Yorio T, etal., eds. Ocular Therapeutics: Eye on New Discoveries. New York: Elsevier Press/Academic Press, 2010: 7-43.
8. Rajas NJ, etal. In situ ophthalmic gels: a developing trend. Int J Pharm Sci Rev Res 2011; 7: 8-14.
9. Järvinen T, Järvinen K,. Prodrugs for improved ocular drug delivery. Adv Drug Deliv Rev 1996; 19: 203-224.
10. Diebold Y, Calonge M,. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010; 29: 596-609.
11. Giannavola C, etal. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003; 4: 584-590.
12. Fresta M, etal. Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir. J Pharm Pharmacol 1999; 51: 565-576.
13. Zimmer A, Kreuter J,. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 1995; 16: 61-73.
14. Ali M, etal. Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow. J Control Release 2007; 124: 154-162.
15. Kikuchi T, etal. Mechanism of permeability-enhancing effect of EDTA and boric acid on the corneal penetration of 4-[1-hydroxy-1-methylethyl]-2-propyl-1- [4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088). Int J Pharm 2005; 299: 107-114.
16. Reddy IK, Bodor NS,. Novel approaches to design and deliver safe and effective antiglaucoma agents to the eye. Adv Drug Deliv Rev 1994; 14: 251-267.
17. Quigley HA,. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-393.
18. Mediero A, etal. New treatments for ocular hypertension. Auton Neurosci 2009; 147: 14-19.
19. Lang JC,. Ocular drug delivery: conventional ocular formulations. Adv Drug Deliv Rev 1995; 16: 39-43.
20. Gaudana R, etal. Recent perspectives in ocular drug delivery. Pharm Res 2009; 26: 1197-1216.
21. Kumaran KSGA, etal. Comparative review on conventional and advanced drug delivery formulations. Int J Pharm Pharm Sci 2010; 2: 1-5.
22. Cunha-Vaz J,. The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp Eye Res 2004; 78: 715-721.
23. Rathore KS, Nema RK,. An insight into ophthalmic drug delivery. Int J Pharm Sci Drug Res 2009; 1: 1-5.
24. Chang JN,. Recent advances in ophthalmic drug delivery. In:, Kulkarn VS, ed. Handbook of Non-Invasive Drug Delivery Systems. New York: William Andrew Publishing, 2010: 165-192.
25. Presl A, Myatt J,. Ocular anatomy and physiology relevant to anaesthesia. Anaesth Intensive Care 2010; 11: 391-450.
26. Bourlais CL, etal. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res 1998; 17: 33-58.
27. Saettone MF, etal. Controlled release of timolol maleate from coated ophthalmic mini-tablets prepared by compression. Int J Pharm 1995; 126: 79-82.
28. Urtti A,. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131-1135.
29. Barar J, etal. Ocular drug delivery: impact of in vitro cell culture models. J Ophthalmic Vis Res 2009; 4: 238-252.
30. Mannerma E, etal. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006; 58: 1136-1163.
31. Patel S, etal. Refractive index change in bovine and human corneal stroma before and after LASIK: a study of untreated and re-treated corneas implicating stromal hydration. Invest Ophthalmol Vis Sci 2004; 45: 3523-3530.
32. Edwards A, Prausnitz MP,. Predicted permeability of the cornea to topical drugs. Pharm Res 2001; 11: 1497-1508.
33. Andres-Guerrero V, Herrero-Vanrell R,. Ocular drug absorption by topical route. Role of conjunctiva. Arch Soc Esp Oftalmol 2008; 83: 683-686.
34. Hornof M, etal. Cell culture models of the ocular barriers. Eur J Pharm Biopharm 2005; 60: 207-225.
35. Geroski DH, Edelhauser HF,. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 2000; 41: 961-964.
36. Short BS,. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol 2008; 36: 49-62.
37. Ahmed I,. The noncorneal route in ocular drug delivery. In:, Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker, 2003: 335-363.
38. Thrimawithana TR, etal. Drug delivery to the posterior segment of the eye. Drug Discov Today 2010; 16: 270-277.
39. Raghava S, etal. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 2004; 1: 99-114.
40. Davis JL, etal. Novel approaches to ocular drug delivery. Curr Opin Mol Ther 2004; 6: 195-205.
41. Wilson CG,. Topical drug delivery in the eye. Exp Eye Res 2004; 78: 737-743.
42. Urtti A, etal. Controlled drug delivery devices for experimental ocular studies with timolol. Ocular and systemic absorption in rabbits. Int J Pharm 1990; 61: 241-249.
43. Chowhan M, etal. Drug delivery-ophthalmic route. In:, Swarbrick J, Boylan JC, eds. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, 2002: 863-870.
44. Hosoya K, etal. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm 2005; 60: 227-240.
45. Noecker R,. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18: 205-215.
46. Davies NM,. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000; 27: 558-562.
47. Macdonald EA, Maurice DM,. Loss of fluorescein across the conjunctiva. Exp Eye Res 1991; 53: 427-430.
48. Gonjari ID, etal. Formulation and evaluation of in situ gelling thermoreversible mucoadhesive gel of fluconazole. Drug Discov Ther 2009; 3: 6-9.
49. Lux A, etal. A comparative bioavailability study of three conventional eye drops versus a single lyophilisate. Br J Ophthalmol 2003; 87: 436-440.
50. Schwartz GF, Quigley HA,. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008; 53: 57-68.
51. Fraunfelder FW,. Corneal toxicity from topical ocular and systemic medications. Cornea 2006; 25: 1133-1138.
52. Manish K, Kulkarni GT,. Recent advances in ophthalmic drug delivery. Int J Pharm Pharm Sci 2012; 4: 387-394.
53. Saettone FM, etal. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four β-blockers, and in vitro/in vivo toxic activity. Int J Pharm 1996; 142: 103-113.
54. Furrer P, Mayer JM,. Ocular tolerance of absorption enhancers in ophthalmic preparations. AAPS PharmSciTech 2002; 4: 6-10.
55. Janoria KG, etal. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007; 4: 371-388.
56. Torchilin VP,. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4: 145-160.
57. Kumar S, etal. In situ-forming gels for ophthalmic drug delivery. J Ocul Pharmacol 1994; 10: 47-56.
58. Nanjawade BK, etal. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release 2007; 122: 119-134.
59. Lennartz P, Mielck JB,. Minitabletting: improving the compactability of paracetamol powder mixtures. Int J Pharm 1998; 173: 75-85.
60. Follonier N,. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms. STP Pharm Sci 1992; 2: 141-158.
61. Munday DL,. A comparison of the dissolution characteristics of theophylline from film-coated granules and mini-tablets. Drug Dev Ind Pharm 1994; 20: 2369-2379.
62. Lopes CM, etal. Compressed mini-tablets as a biphasic delivery system. Int J Pharm 1996; 323: 93-100.
63. Tissen C, etal. Development of mini-tablets with 1mm and 2mm diameter. Int J Pharm 2011; 416: 164-170.
64. Stoltenberg I, Breitkreutz J,. Orally disintegrating mini-tablets (ODMTs)-a novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm 2011; 78: 462-469.
65. Urtti A, Salminen L,. Minimizing systemic absorption of topically administered ophthalmologic drugs. Surv Ophthalmol 1993; 37: 435-456.
66. Saettone MI, etal. Controlled release of pilocarpine from coated polymeric ophthalmic inserts prepared by extrusion. Int J Pharm 1992; 86: 159-166.
67. Di Colo G, etal. Gel forming erodible inserts for ocular controlled delivery of ofloxacin. Int J Pharm 1995; 21: 1-8.
68. Saettone MF, Salimen L,. Ocular inserts for topical delivery. Adv Drug Deliv Rev 1995; 16: 95-106.
69. Refai H, Tag R,. Development and characterization of sponge-like acyclovir ocular minitablets. Drug Deliv 2011; 18: 38-45.
70. Ceulemans J, etal. Evaluation of a mucoadhesive tablet for ocular use. J Control Release 2001; 77: 333-344.
71. Weyenberg W, etal. Characterization and in vivo minitablets compressed at different forces. J Control Release 2003; 89: 329-340.
72. Weyenberg W, etal. Effects of roller compaction settings on the preparation of bioadhesive granules and ocular minitablets. Eur J Pharm Biopharm 2005; 59: 527-536.
73. Thakur RR, Kashiv M,. Modern delivery systems for ocular drug formulations: a comparative overview W.R.T conventional dosage form. Int J Res Pharm Biomed Sci 2011; 1: 8-18.
74. Lin CP, Boehnke M,. Influences of methylcellulose on corneal epithelial wound healing. J Ocul Pharmacol Ther 1999; 15: 59-63.
75. Calonge M,. The treatment of dry eye. Surv Ophthalmol 2001; 45: 227-239.
76. Toda I, etal. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjogren's syndrome. Cornea 1996; 15: 120-128.
77. Ludwig A,. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005; 57: 1595-1639.
78. Mortazavi SA, etal. Formulation and in-vitro evaluation of ocular ciprofloxacin-containing minitablets prepared with different combinations of carbopol 974P and various cellulose derivatives. Iran J Pharm Res 2010; 9: 107-114.
79. Kumar S, Himmelstein KJ,. Modification of in situ gelling behavior of carbopol solutions by hydroxypropyl methylcellulose. J Pharm Sci 1995; 84: 344-348.
80. Davies NM, etal. Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions. Pharm Res 1991; 8: 1039-1043.
81. Motwani SK, etal. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization. Eur J Pharm Biopharm 2008; 68: 513-525.
82. Rajendran NN, etal. Acyclovir-loaded chitosan nanoparticles for ocular delivery. Asian J Pharm 2010; 4: 220-226.
83. Dudhani AR, Kosaraju SL,. Bioadhesive chitosan nanoparticles: preparation and characterization. Carbohydr Polym 2010; 81: 243-251.
84. Lehr CM, etal. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992; 78: 43-48.
85. Gratieri T, etal. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010; 75: 186-193.
86. Gad SC,. Schematic of amylopectin structure. In: Pharmaceutical Manufacturing Handbook: Production and Processes. Hoboken, NJ: John Wiley and Sons, Inc., 2008.
87. Olayemi OJ, etal. Comparative evaluation of maize, rice and wheat starch powders as pharmaceutical excipients. Niger J Pharm Sci 2008; 1: 131-138.
88. Yan H, Zhengbiao GU,. Morphology of modified starches prepared by different methods. Food Res Int 2010; 3: 767-772.
89. Callens C, etal. Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability. Int J Pharm 2003; 2: 415-422.
90. Weyenberg W, etal. Characterization and in vivo evaluation of ocular minitablets prepared with different bioadhesive Carbopol-starch components. Eur J Pharm Biopharm 2006; 62: 202-209.
91. Gasthuys F, etal. Evaluation of the in vivo behaviour of gentamicin sulphate ocular mini-tablets in ponies. J Vet Pharmacol Ther 2007; 30: 470-476.
92. Choy YB, etal. Mucoadhesive microdiscs engineered for ophthalmic drug delivery: effect of particle geometry and formulation on preocular residence time. Invest Ophthalmol Vis Sci 2008; 11: 4808-4815.
93. Bozdag S, etal. In vitro evaluation of gentamicin- and vancomycin-containing minitablets as a replacement for fortified eye drops. Drug Dev Ind Pharm 2010; 36: 1259-1270.
94. Gilhotr RM, etal. A hydrogel-forming bioadhesive ocular minitablet for the management of microbial keratitis. Asian J Pharm Sci 2010; 5: 19-25.
95. Gurtler F, etal. Long-acting bioadhesive ophthalmic drug insert (BODI) containing gentamicin for veterinary use: optimization and clinical investigation. J Control Release 1995; 33: 231-236.
96. Unterman SR, etal. Collagen shield drug delivery: therapeutic concentrations of tobramycin in the rabbit eye and aqueous humour. J Cataract Refract Surg 1988; 15: 500-504.
97. O'Brien TP, etal. Use of collagen corneal shields versus soft contact lenses to enhance penetration of topical tobramycin. J Cataract Refract Surg 1988; 14: 505-507.
98. Diestelhorst M, etal. Dry drops: a new preservative-free drug delivery system. Graefes Arch Clin Exp Ophthalmol 1995; 237: 394-398.
99. Kim H, etal. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci 2005; 46: 655-662.
100. Simamora P, etal. Controlled delivery of pilocarpine. 2. In vivo evaluation of Gelfoam device. Int J Pharm 1998; 170: 209-214.
101. Bawa R,. Ocular inserts. In:, Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker Inc., 1993: 223-260.
102. Kuno N, Fujii S,. Recent advances in ocular drug delivery systems. Polymers 2011; 3: 193-221.
103. Lawrenson JG, etal. Comparison of the efficacy and duration of action of topically applied proxymetacaine using a novel ophthalmic delivery system versus eye drops in healthy young volunteers. Br J Ophthalmol 1993; 77: 713-775.
104. Quigley HA, etal. Pilocarpine ocuserts. Long term clinical trials and selected pharmacodynamics. Arch Ophthalmol 1975; 93: 771-775.
105. Chetoni P, etal. Silicone rubber/hydrogel composite ophthalmic inserts: preparation and preliminary in vitro/in vivo evaluation. Eur J Pharm Biopharm 1998; 46: 125-132.
106. Tai MC, etal. The clinical efficacy of silicone punctal plug therapy. Cornea 2002; 2: 135-139.
107. ClinicalTrials.gov. Safety and efficacy of a glaucoma drug delivery system. http://clinicaltrials.gov/ct2/show/NCT00824720 [updated 26 September 2011, accessed 17 November 2011].
108. ClinicalTrials.gov. Safety study of latanoprost slow release insert (Latanoprost SR). http://clinicaltrials.gov/ct2/show/NCT01180062 [updated 26 September 2011, accessed 17 November 2011].
109. Sihvola P, Puustjärvi T,. Practical problems in the use of Ocusert®-pilocarpine delivery system. Acta Ophthalmol 1980; 58: 933-937.
110. Pierre Y, etal. The impact of ageing on the barriers to drug delivery. J Control Release 2012; 161: 389-398.
111. Mizumoto T, etal. Formulation design of a novel fast disintegrating tablet. Int J Pharm 2005; 306: 83-90.
112. Ciper M, Bodmeier R,. Modified conventional hard gelatin capsules as fast disintegrating dosage form in the oral cavity. Eur J Pharm Biopharm 2008; 62: 178-184.
113. Tsinontides SC, etal. Freeze drying-principles and practice for successful scale-up to manufacturing. Int J Pharm 2004; 280: 1-16.
114. Carpenter JF, etal. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 1997; 14: 969-975.
115. Virely P, Yarwood R,. Zydis-a novel, fast dissolving dosage form. Manuf Chem 1990; 61: 36-37.